4930422G04Rik Inhibitors
Chemical inhibitors of 4930422G04Rik can be used to investigate the functional role of this protein in various cellular signaling pathways. Wortmannin and LY294002 are two such inhibitors that target the phosphoinositide 3-kinase (PI3K) pathway. By inhibiting PI3K, these chemicals prevent the phosphorylation of downstream targets which can lead to the functional inhibition of 4930422G04Rik, assuming it is regulated by PI3K-associated pathways. Another approach to modulate 4930422G04Rik's function is by using MEK inhibitors such as PD98059 and U0126. These compounds specifically inhibit the mitogen-activated protein kinase kinase, which is part of the MAPK/ERK pathway. Disruption of this pathway can lead to a decrease in the functional activity of 4930422G04Rik by preventing the activation of proteins that are upstream or downstream of this signaling cascade.
Additional chemical inhibitors include SB203580, a specific inhibitor of p38 MAP kinase, and SP600125, which targets c-Jun N-terminal kinase (JNK). The inhibition of these kinases can influence the activity of 4930422G04Rik by affecting the cellular responses to stress or cytokines. Rapamycin, an mTOR inhibitor, disrupts signaling required for cell growth and proliferation, which can lead to the functional inhibition of 4930422G04Rik if these processes are essential for its activity. Src family kinases, which can be inhibited by compounds like PP2 and Dasatinib, play a role in various signaling pathways, and their inhibition can also alter the functional state of 4930422G04Rik. Lastly, Gefitinib, Erlotinib, and Lapatinib are inhibitors of tyrosine kinase receptors such as EGFR and HER2/neu. Inhibition of these receptors can lead to functional inhibition of 4930422G04Rik if it is involved in signaling pathways mediated by these receptors.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it can decrease the phosphorylation of downstream targets, potentially leading to functional inhibition of 4930422G04Rik if it is regulated by PI3K signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another inhibitor of PI3K. It prevents the activation of PI3K pathways, which might be crucial for the functional activity of 4930422G04Rik, thus leading to its inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is involved in the MAPK/ERK pathway. Inhibition of this pathway can result in the downregulation of cellular processes that may be essential for the function of 4930422G04Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also an inhibitor of MEK, which disrupts the MAPK/ERK signaling pathway. This could lead to the functional inhibition of 4930422G04Rik by preventing its activation or the activation of proteins within its pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The inhibition of p38 MAP kinase can affect the function of 4930422G04Rik by disrupting cellular responses to stress or cytokines that may be necessary for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. Inhibition of JNK activity can lead to the functional inhibition of 4930422G04Rik by altering transcription factor activity that may regulate 4930422G04Rik function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it disrupts downstream signaling required for cell growth, proliferation, and survival, which could functionally inhibit 4930422G04Rik if these cellular processes are critical for its activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. By inhibiting Src kinases, it can alter downstream signaling pathways that could be essential for the functional activity of 4930422G04Rik. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, including Src family kinases. It can lead to the functional inhibition of 4930422G04Rik by altering the phosphorylation state of proteins within signaling pathways involving 4930422G04Rik. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. By inhibiting EGFR, it could result in the functional inhibition of 4930422G04Rik if EGFR signaling is required for its activity. | ||||||